CIK 2018299
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 91.68% | 48 |
| Unclassified | 4.95% | 5 |
| Health Care Providers & Services | 3.37% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics, Inc. | Health Care | 29.87% |
| 2 | KOD | Kodiak Sciences Inc. | Health Care | 6.81% |
| 3 | RVMD | Revolution Medicines, Inc. | Health Care | 6.38% |
| 4 | KYMR | Kymera Therapeutics, Inc. | Health Care | 3.60% |
| 5 | CELC | Celcuity Inc. | Health Care | 3.37% |
| 6 | SRZN | Surrozen, Inc./DE | Health Care | 2.93% |
| 7 | ABVX | Abivax S.A. | Health Care | 2.92% |
| 8 | TERNS PHARMACEUTICALS INC | Unclassified | 2.60% | |
| 9 | PCVX | Vaxcyte, Inc. | Health Care | 2.48% |
| 10 | CAPR | CAPRICOR THERAPEUTICS, INC. | Health Care | 2.35% |
49/54 names classified · sector 95.1% of weight · industry 95.1% · mkt cap 92.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 95.1% of the book is sector-classified (unclassified names shown, never dropped).
Only 3% of book weight classified — the grid is NOT representative of the whole book.
Classified: 3.1% of book weight (2/52 names) · unclassified 96.9%: TNGX, KOD, RVMD, KYMR, , CELC, SRZN, ABVX, PCVX, CAPR +40 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | TNGXTANGO THERAPEUTICS INC | 10,876,219 | $228M | 29.9% | HOLD |
| 2 | KODKODIAK SCIENCES INC | 1,361,000 | $52M | 6.8% | ADD 20% |
| 3 | RVMDREVOLUTION MEDICINES INC | 500,000 | $49M | 6.4% | ADD 25% |
| 4 | KYMRKYMERA THERAPEUTICS INC | 329,100 | $27M | 3.6% | HOLD |
| 5 | CELCCELCUITY INC | 225,000 | $26M | 3.4% | HOLD |
| 6 | SRZNSURROZEN INC | 766,318 | $22M | 2.9% | ADD 84% |
| 7 | ABVXABIVAX SA | 200,000 | $22M | 2.9% | ADD 60% |
| 8 | TERNS PHARMACEUTICALS INC | 375,000 | $20M | 2.6% | HOLD |
| 9 | PCVXVAXCYTE INC | 325,000 | $19M | 2.5% | NEW |
| 10 | CAPRCAPRICOR THERAPEUTICS INC | 590,000 | $18M | 2.4% | ADD 82% |
| 11 | PTGXPROTAGONIST THERAPEUTICS INC | 170,000 | $18M | 2.4% | HOLD |
| 12 | VIRVIR BIOTECHNOLOGY INC | 1,866,000 | $17M | 2.2% | ADD 199% |
| 13 | CRVSCORVUS PHARMACEUTICALS INC | 1,100,000 | $16M | 2.1% | NEW |
| 14 | PRAXPRAXIS PRECISION MEDICINES I | 46,457 | $15M | 2.0% | HOLD |
| 15 | PTCTPTC THERAPEUTICS INC | 200,000 | $14M | 1.8% | HOLD |
| 16 | PGENPRECIGEN INC | 3,500,000 | $14M | 1.8% | ADD 155% |
| 17 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 598,500 | $11M | 1.5% | NEW |
| 18 | AMLXAMYLYX PHARMACEUTICALS INC | 800,000 | $11M | 1.5% | HOLD |
| 19 | QUREUNIQURE NV | 662,000 | $11M | 1.4% | ADD 128% |
| 20 | IRDOPUS GENETICS INC | 2,250,000 | $10M | 1.3% | NEW |
| 21 | CORTCORCEPT THERAPEUTICS INC | 250,000 | $10M | 1.3% | NEW |
| 22 | URGNUROGEN PHARMA LTD | 500,000 | $9M | 1.2% | HOLD |
| 23 | REPLREPLIMUNE GROUP INC | 1,175,000 | $9M | 1.2% | ADD 57% |
| 24 | COGTCOGENT BIOSCIENCES INC | 225,000 | $9M | 1.1% | HOLD |
| 25 | PALIPALISADE BIO INC | 4,799,875 | $8M | 1.1% | HOLD |
| 26 | CBIOCrescent Biopharma Inc | 453,686 | $8M | 1.1% | NEW |
| 27 | SOLENO THERAPEUTICS INC | 200,000 | $7M | 0.9% | NEW |
| 28 | ALLOALLOGENE THERAPEUTICS INC | 2,725,000 | $7M | 0.9% | NEW |
| 29 | CYTKCYTOKINETICS INC | 100,000 | $7M | 0.9% | HOLD |
| 30 | CTNMCONTINEUM THERAPEUTICS INC | 494,000 | $6M | 0.8% | HOLD |
| 31 | APGEAPOGEE THERAPEUTICS INC | 70,000 | $6M | 0.8% | HOLD |
| 32 | RLMDRELMADA THERAPEUTICS INC | 842,106 | $6M | 0.8% | NEW |
| 33 | ZURAZURA BIO LTD | 900,000 | $5M | 0.7% | ADD 1700% |
| 34 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 275,000 | $5M | 0.7% | HOLD |
| 35 | AVTXAVALO THERAPEUTICS INC | 300,000 | $4M | 0.6% | ADD 9% |
| 36 | INOINOVIO PHARMACEUTICALS INC | 2,370,122 | $4M | 0.5% | TRIM −2% |
| 37 | GPCRSTRUCTURE THERAPEUTICS INC | 75,000 | $4M | 0.5% | HOLD |
| 38 | SRPTSAREPTA THERAPEUTICS INC | 150,000 | $3M | 0.4% | HOLD |
| 39 | HELPCYBIN INC | 640,000 | $3M | 0.4% | TRIM −10% |
| 40 | OCULOCULAR THERAPEUTIX INC | 350,000 | $3M | 0.4% | NEW |
| 41 | ANTXAN2 THERAPEUTICS INC | 749,035 | $3M | 0.3% | NEW |
| 42 | CLNNCLENE INC | 477,515 | $2M | 0.3% | ADD 139% |
| 43 | ORICORIC PHARMACEUTICALS INC | 176,500 | $2M | 0.3% | NEW |
| 44 | SLDBSOLID BIOSCIENCES INC | 300,000 | $2M | 0.3% | HOLD |
| 45 | IVVDINVIVYD INC | 1,500,000 | $2M | 0.3% | HOLD |
| 46 | LBRXLB PHARMACEUTICALS INC | 70,000 | $2M | 0.2% | HOLD |
| 47 | KPTIKARYOPHARM THERAPEUTICS INC | 302,536 | $2M | 0.2% | ADD 20% |
| 48 | NRIXNURIX THERAPEUTICS INC | 100,000 | $2M | 0.2% | HOLD |
| 49 | UPBUPSTREAM BIO INC | 150,000 | $1M | 0.2% | HOLD |
| 50 | MISTMILESTONE PHARMACEUTICALS IN | 666,666 | $793,333 | 0.1% | HOLD |
| 51 | PEPGPEPGEN INC | 272,892 | $483,019 | 0.1% | TRIM −27% |
| 52 | KALVISTA PHARMACEUTICALS INC | 20,400 | $410,652 | 0.1% | HOLD |
| 53 | RGNXREGENXBIO INC | 15,000 | $125,700 | 0.0% | NEW |
| 54 | SRZNWSURROZEN INC | 66,666 | $1,067 | 0.0% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| TNGXTANGO THERAPEUTICS INC | 10.4M | 10.4M | 9.8M | 9.8M | 10.9M | 10.9M | $228M |
| KODKODIAK SCIENCES INC | 1.0M | 1.0M | 750K | 750K | 1.1M | 1.4M | $52M |
| RVMDREVOLUTION MEDICINES INC | 4.3M | 1.3M | 793K | 400K | 400K | 500K | $49M |
| KYMRKYMERA THERAPEUTICS INC | 425K | 325K | 432K | 319K | 329K | 329K | $27M |
| CELCCELCUITY INC | — | — | — | 90K | 225K | 225K | $26M |
| SRZNSURROZEN INC | — | — | — | — | 416K | 766K | $22M |
| ABVXABIVAX SA | — | — | — | 120K | 125K | 200K | $22M |
| TERNS PHARMACEUTICALS INC | 752K | — | — | — | 375K | 375K | $20M |
| PCVXVAXCYTE INC | — | — | — | — | — | 325K | $19M |
| CAPRCAPRICOR THERAPEUTICS INC | — | — | — | — | 325K | 590K | $18M |
| PTGXPROTAGONIST THERAPEUTICS INC | — | — | 60K | 110K | 170K | 170K | $18M |
| VIRVIR BIOTECHNOLOGY INC | — | — | — | — | 625K | 1.9M | $17M |
| CRVSCORVUS PHARMACEUTICALS INC | — | — | — | — | — | 1.1M | $16M |
| PRAXPRAXIS PRECISION MEDICINES I | — | — | — | — | 46K | 46K | $15M |
| PTCTPTC THERAPEUTICS INC | — | — | — | 200K | 200K | 200K | $14M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
